BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36878807)

  • 41. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
    Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Older age, symptoms, or anemia: Which factors increase colorectal cancer risk with a positive fecal immunochemical test?
    Hamarneh Z; Symonds EL; Kholmurodova F; Cock C
    J Gastroenterol Hepatol; 2020 Jun; 35(6):1002-1008. PubMed ID: 31606908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
    Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
    JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia.
    Kapidzic A; van der Meulen MP; Hol L; van Roon AH; Looman CW; Lansdorp-Vogelaar I; van Ballegooijen M; van Vuuren AJ; Reijerink JC; van Leerdam ME; Kuipers EJ
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1464-71.e4. PubMed ID: 25724706
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
    Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
    Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.
    de Klerk CM; Vendrig LM; Bossuyt PM; Dekker E
    Am J Gastroenterol; 2018 Dec; 113(12):1778-1787. PubMed ID: 30158713
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Efficacy comparison among high risk factors questionnaire and Asia-Pacific colorectal screening score and their combinations with fecal immunochemical test in screening advanced colorectal tumor].
    Zhu N; Huang YQ; Song YM; Zhang SZ; Zheng S; Yuan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jul; 25(7):612-620. PubMed ID: 35844124
    [No Abstract]   [Full Text] [Related]  

  • 49. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
    Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
    Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.
    Robertson DJ; Lee JK; Boland CR; Dominitz JA; Giardiello FM; Johnson DA; Kaltenbach T; Lieberman D; Levin TR; Rex DK
    Gastroenterology; 2017 Apr; 152(5):1217-1237.e3. PubMed ID: 27769517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Similar fecal immunochemical test results in screening and referral colorectal cancer.
    van Turenhout ST; van Rossum LG; Oort FA; Laheij RJ; van Rijn AF; Terhaar sive Droste JS; Fockens P; van der Hulst RW; Bouman AA; Jansen JB; Meijer GA; Dekker E; Mulder CJ
    World J Gastroenterol; 2012 Oct; 18(38):5397-403. PubMed ID: 23082056
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification and Validation of MicroRNA Profiles in Fecal Samples for Detection of Colorectal Cancer.
    Duran-Sanchon S; Moreno L; Augé JM; Serra-Burriel M; Cuatrecasas M; Moreira L; Martín A; Serradesanferm A; Pozo À; Costa R; Lacy A; Pellisé M; Lozano JJ; Gironella M; Castells A
    Gastroenterology; 2020 Mar; 158(4):947-957.e4. PubMed ID: 31622624
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short Term Outcomes of Using Fecal Immunochemical Test for a Pilot Colorectal Cancer Screening Program. A Single Center Study on 3024 Consecutive Patients.
    Constantin A; Cazacu I; Ciocârlan M; Constantinescu C; Baltog G; Balahura C; Doraş I; Filip S; Filip G; Panazan I; Piţigoi D; Pirvu V; Turcu F; Copăescu C; Săftoiu A
    Chirurgia (Bucur); 2020; 115(4):448-457. PubMed ID: 32876018
    [No Abstract]   [Full Text] [Related]  

  • 54. Triage Process at Endoscopy With ColonView Fecal Immunochemical Test (FIT) Will Enhance Diagnostic Accuracy (DA) of Colorectal Cancer Screening.
    Eskelinen M; Meklin J; Guimaraes DP; Selander T; Syrjänen K; Eskelinen M
    Anticancer Res; 2023 Dec; 43(12):5535-5544. PubMed ID: 38030208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening.
    Kooyker A; de Jonge L; Toes-Zoutendijk E; Spaander M; van Vuuren H; Kuipers E; van Kemenade F; Ramakers C; Dekker E; Nagtegaal I; van Leerdam M; Lansdorp-Vogelaar I
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3424-3432.e2. PubMed ID: 37619823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A delay in the diagnosis of colorectal cancer screened by fecal immunochemical tests during the COVID-19 pandemic: a longitudinal cohort study.
    Ishibashi F; Shida D; Suzuki S; Nagai M; Mochida K; Morishita T
    Int J Colorectal Dis; 2022 Dec; 37(12):2543-2546. PubMed ID: 36383225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. One or two faecal immunochemical tests in an organised population-based colorectal cancer screening programme in Murcia (Spain).
    Tourne-Garcia C; Perez-Riquelme F; Monteagudo-Piqueras O; Fraser CG; Yepes-Garcia P
    J Med Screen; 2022 Dec; 29(4):231-240. PubMed ID: 35578555
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk stratification for colorectal neoplasia detection in the Flemish colorectal cancer screening programme.
    van de Veerdonk W; Van Hal G; Peeters M; De Brabander I; Silversmit G; Hoeck S
    Cancer Epidemiol; 2018 Oct; 56():90-96. PubMed ID: 30114631
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia.
    Grobbee EJ; Schreuders EH; Hansen BE; Bruno MJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
    Gastroenterology; 2017 Nov; 153(5):1251-1259.e2. PubMed ID: 28760383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.